Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04731233 · ClinicalTrials.gov registry record · Phase 4
Efficacy of PRGF Supplementation After TMJ Arthrocentesis in Patients With TMJ Osteoarthritis
A Phase 4 study, sponsored by University of Florida.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT04731233: Clinical Trial Phase 4 study, sponsored by University of Florida.
NCT04731233 is a Phase 4 study that was terminated before completion, run by University of Florida. The registered enrollment target is 5 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04731233, a Phase 4 study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
Temporomandibular joint (TMJ) osteoarthritis (OA) affects articulating tissues secondary to inflammation resulting in intracapsular pain. This prospective, double-blind randomized clinical trial will evaluate the relative efficacy of TMJ arthrocentesis with a supplementation of platelet-rich growth factors (PRGF) compared to TMJ arthrocentesis with a steroid supplementation (a known effective therapy) for patients with TMJ OA.
Primary Outcome
The Visual Analog Scale (VAS) is a pain rating scale that has a range of 0-100 and is represented as a 100 mm line. On this scale, 0 is represented as "no pain" and 100 is represented as "the most intense pain imaginable". Pain is measured by having the subject place a line bisecting a 100 mm line to represent the pain level and a numerical rating is obtained by measuring the distance, in mm, from the zero-pain anchor (left side of scale represented by 0 pain).
Interventions
- DRUG Triamcinolone Acetonide
- BIOLOGICAL Plasma Rich in Growth Factor (PRGF) Supplementation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-03-30 |
| Est. Completion | 2024-02-21 |
| Phase | Phase 4 |
Why NCT04731233 stopped before completion
NCT04731233 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Triamcinolone Acetonide is the first listed.
NCT04731233 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04731233 about?
NCT04731233 is a clinical study titled "Efficacy of PRGF Supplementation After TMJ Arthrocentesis in Patients With TMJ Osteoarthritis". Temporomandibular joint (TMJ) osteoarthritis (OA) affects articulating tissues secondary to inflammation resulting in intracapsular pain. This prospective, double-blind randomized clinical trial will evaluate the relative efficacy of TMJ arthrocentesis with a supplementation of platelet-rich growth ...
What is the current status of trial NCT04731233?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2021-03-30. Estimated completion is 2024-02-21.
What interventions are being tested in trial NCT04731233?
The interventions under investigation include: Triamcinolone Acetonide (DRUG), Plasma Rich in Growth Factor (PRGF) Supplementation (BIOLOGICAL).
Who is sponsoring clinical trial NCT04731233?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04731233's enrollment target sits among peer trials
5 1989th of 2000 higher than 7 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI